• Login
    View Item 
    •   Home
    • 1 Published Research and Commentary
    • Trypanosomiasis/Sleeping Sickness
    • View Item
    •   Home
    • 1 Published Research and Commentary
    • Trypanosomiasis/Sleeping Sickness
    • View Item
    Jan 19, 2021
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of MSFTitleAuthorsSubjectsPublisherJournalThis CollectionTitleAuthorsSubjectsPublisherJournal

    Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Médecins Sans Frontières programmes.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    Balasegaram Transactions Oct ...
    Size:
    314.1Kb
    Format:
    PDF
    Download
    Authors
    Balasegaram, M
    Young, H
    Chappuis, F
    Priotto, G
    Raguenaud, M E
    Checchi, F
    Affiliation
    Médecins Sans Frontières-United Kingdom, 67-74 Saffron Hill, London EC1N 8QX, UK.
    Issue Date
    2008-10-21
    
    Metadata
    Show full item record
    Journal
    Transactions of the Royal Society of Tropical Medicine and Hygiene
    Abstract
    This paper describes the effectiveness of first-line regimens for stage 2 human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense infection in nine Médecins Sans Frontières HAT treatment programmes in Angola, Republic of Congo, Sudan and Uganda. Regimens included eflornithine and standard- and short-course melarsoprol. Outcomes for 10461 naïve stage 2 patients fitting a standardised case definition and allocated to one of the above regimens were analysed by intention-to-treat analysis. Effectiveness was quantified by the case fatality rate (CFR) during treatment, the proportion probably and definitely cured and the Kaplan-Meier probability of relapse-free survival at 12 months and 24 months post admission. The CFR was similar for the standard- and short-course melarsoprol regimens (4.9% and 4.2%, respectively). The CFR for eflornithine was 1.2%. Kaplan-Meier survival probabilities varied from 71.4-91.8% at 1 year and 56.5-87.9% at 2 years for standard-course melarsoprol, to 73.0-91.1% at 1 year for short-course melarsoprol, and 79.9-97.4% at 1 year and 68.6-93.7% at 2 years for eflornithine. With the exception of one programme, survival at 12 months was >90% for eflornithine, whilst for melarsoprol it was <90% except in two sites. Eflornithine is recommended where feasible, especially in areas with low melarsoprol effectiveness.
    URI
    http://hdl.handle.net/10144/41787
    DOI
    10.1016/j.trstmh.2008.09.005
    PubMed ID
    18947846
    Language
    en
    ISSN
    0035-9203
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.trstmh.2008.09.005
    Scopus Count
    Collections
    Trypanosomiasis/Sleeping Sickness

    entitlement

    Related articles

    • Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo.
    • Authors: Priotto G, Kasparian S, Ngouama D, Ghorashian S, Arnold U, Ghabri S, Karunakara U
    • Issue date: 2007 Dec 1
    • Eflornithine is a cost-effective alternative to melarsoprol for the treatment of second-stage human West African trypanosomiasis in Caxito, Angola.
    • Authors: Robays J, Raguenaud ME, Josenando T, Boelaert M
    • Issue date: 2008 Feb
    • Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial.
    • Authors: Pépin J, Khonde N, Maiso F, Doua F, Jaffar S, Ngampo S, Mpia B, Mbulamberi D, Kuzoe F
    • Issue date: 2000
    • [A trial treatment with eflornithine of trypanosomiasis caused by Trypanosoma brucei gambiense in the Peoples Republic of the Congo].
    • Authors: Eozenou P, Jannin J, Ngampo S, Carme B, Tell GP, Schechter PJ
    • Issue date: 1989 Apr-Jun
    • Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial.
    • Authors: Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, Arnold U, Ghabri S, Baudin E, Buard V, Kazadi-Kyanza S, Ilunga M, Mutangala W, Pohlig G, Schmid C, Karunakara U, Torreele E, Kande V
    • Issue date: 2009 Jul 4
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.